Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
01 Apr 2022
Empagliflozin benefits similar between MRA users, nonusers
In patients with heart failure (HF) and preserved ejection fraction, treatment with empagliflozin delivers comparable benefits in reducing first hospitalization for HF or cardiovascular death (primary outcome) between users and nonusers of mineralocorticoid receptor antagonists (MRA), reports a study.
Empagliflozin benefits similar between MRA users, nonusers
31 Mar 2022
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
Use of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) appears to reduce venous thromboembolism (VTE) in major noncardiac surgery compared with no active treatment, a study has shown. However, it may also increase major bleeding to a similar extent.
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
30 Mar 2022
Methenamine hippurate prevents recurrent UTI in women
Nonantibiotic treatment with methenamine hippurate shows high levels of efficacy in women with a history of recurrent episodes of urinary tract infection (UTI), which is comparable to the current guideline-recommended prophylaxes (ie, long-course, low-dose antibiotics), according to a study.
Methenamine hippurate prevents recurrent UTI in women
29 Mar 2022
BP-lowering drugs reduce death in older hypertensive COVID-19 patients
Antecedent use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) among older COVID-19 patients with hypertension results in fewer all-cause deaths, whether in-hospital or shortly after discharge, compared with no antecedent use of renin-angiotensin system inhibitors (RASIs), a study has shown.
BP-lowering drugs reduce death in older hypertensive COVID-19 patients
29 Mar 2022
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.